The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer.

Both total macrophages (CD45 + F4/80 + ) and CD11c − macrophages trended toward increases with R848, but did not reach statistical significance.

also in 111,027 other papers